Show Summary Details
Page of

Biomarkers in acute heart failure 

Biomarkers in acute heart failure
Chapter:
Biomarkers in acute heart failure
Author(s):

Rajiv Choudhary

, Kevin Shah

, and Alan Maisel

DOI:
10.1093/med/9780199687039.003.0037_update_003

Update:

Meta-analyses included confirming the utility of BNP, NT-proBNP, and MR-proANP as negative predictors for acute heart failure and the utility of NT-proBNP-guided outpatient HF management.

Discussion added on a novel therapeutic agent for heart failure with reduced ejection fraction: sacubitril-valsartan (LCZ696).

References added on biomarkers galectin-3, neutrophil gelatinase-associated lipocalin, and procalcitonin.

A model utilizing a panel of biomarkers to assess response to diuretics in acute HF is included as a potential additional role for biomarkers in AHF.

The prognostic value of endothelin in acute HF for short and long-term outcomes was included.

The recently published American Heart Association (AHA) Scientific Statement on Biomarkers in HF was mentioned and cited.

3 new references

Updated on 22 February 2018. The previous version of this content can be found here.
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 20 October 2019

Acute heart failure continues to be a worldwide medical problem, associated with frequent readmissions, high mortality, and a profound economic impact on national health care systems. In the past decade, biomarkers have shifted the way in which acute heart failure is managed by the cardiologist. The search for the ideal biomarker to aid in the diagnosis, prognosis, and treatment of acute heart failure is ongoing. The natriureticfc peptides have proved extremely useful in determining whether acute dyspnoea has a cardiac aetiology. In addition, recent trials have demonstrated the use of natriuretic peptides in inpatient and outpatient prognosis, as well as in titrating medications in outpatients with chronic heart failure to prevent acute heart failure hospitalizations. Other emerging acute heart failure biomarkers include mid-regional pro-adrenomedullin, mid-regional proatrial natriuretic peptide, troponin, ST2, and neutrophil gelatinase-associated lipocalin.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.